Posts Archive

What is the best diet for myeloma patients to build a strong immune system? IMF

NCCN Patient Webinar: Multiple Myeloma

Multiple Myeloma Research Foundation - MMRF - Learn Your Labs | High Impact Topic (HIT)

NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma

NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe

NIH: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version

NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3

NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma

FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone

NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex

NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide

NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM

Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 06/26/2021

NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)

Abecma: CART Cell Therapy -FDA Approves First Cell-Based Gene Therapy for Adult Patients with RRMM

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM

NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)

What is Myeloma? | Cancer Research UK 2021

PE: CRI - Cancer Research Institute: Cellular Therapies: TIL, TCR, CAR T, and NK Cell Therapies

NIH: Clinical Trials: Bringing Cancer Research to All Possible Participants